CDT Equity Inc. (CDT)
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
CDT Equity Inc.
No short interest data available.
Past the 1:250 Nasdaq cap, ineligible for a bid-price compliance period
- 1:20Reverse splitNov 6, 202620 shares → 1
- 1:25Reverse splitSep 29, 202625 shares → 1
- 1:10Reverse splitJul 20, 202610 shares → 1
- 1:25Reverse splitMar 27, 202625 shares → 1
- 1:8Reverse splitOct 13, 20258 shares → 1
- 1:15Reverse splitMay 20, 202515 shares → 1
- 1:100Reverse splitJan 27, 2025100 shares → 1
- 1:2Reverse splitJul 15, 20042 shares → 1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - |
| Research and Development | $5.05M | $3.38M | $90K | $111K | $283K |
| Selling, General, and Administrative | $31.7M | $12.04M | $5.17M | $3.05M | $2.89M |
| Other | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $36.76M | $15.42M | $5.26M | $3.16M | $3.17M |
| Operating Income (EBIT) | -$36.76M | -$15.42M | -$5.26M | -$3.16M | -$3.17M |
| Operating Margin | - | - | - | - | - |
| Interest Expense | $319K | $1.51M | $211K | $0 | $0 |
| Interest Income | $28K | $13K | $15K | $1.98M | $0 |
| Other Income (Expense) | -$2.47M | -$2.38M | $8.1M | -$1.73M | -$484K |
| Income Before Tax (EBT) | -$39.22M | -$17.8M | $2.84M | -$4.89M | -$3.66M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$39.22M | -$17.8M | -$535K | -$4.89M | -$3.66M |
| Net Income Margin | - | - | - | - | - |
| Supplementary Data | |||||
| EPS | -11778.00 | -615930.00 | -23970.00 | -201360.00 | -750.00 |
| Diluted EPS | -11778.00 | -615930.00 | -267600.00 | -201360.00 | -750.00 |
| Weighted Average OS | 3,330 | 29 | 22 | 24 | 5.762 |
| EBITDA | -$36.48M | -$15.84M | $3.05M | -$4.89M | -$3.66M |
| EBITDA Margin | - | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $389.89M | $554K | $4.23M | $0 | $49K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $389.89M | $554K | $4.23M | $0 | $49K |
| Accounts Receivable | $462.85M | $489K | $0 | $0 | $0 |
| Inventory | $402.35M | $0 | $0 | $0 | $0 |
| Other Current Assets | $94.3M | $0 | $0 | $0 | $0 |
| Total Current Assets | $1.35B | $2.71M | $5.73M | $0 | $104K |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $566.02M | $303K | $0 | $0 | $0 |
| Goodwill | $1.04B | $1.02B | $0 | $0 | $0 |
| Intangible Assets | $399.8M | $419.07M | $0 | $5K | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $14.51M | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $177.09M | -$1.44M | $1.49M | $0 | $109K |
| Total Long-Term Assets | $2.19B | $1.48M | $1.49M | $5K | $109K |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $3.54B | $4.19M | $7.22M | $5K | $213K |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $361.43M | $1.43M | $215K | $0 | $0 |
| Short-Term Debt | $0 | $7.23M | $985K | $175K | $177K |
| Current Income Tax Payable | $0 | $0 | $0 | $375K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $3K | $15K |
| Total Current Liabilities | $697.5M | $10.74M | $1.8M | $4K | $193K |
| Long-Term Liabilities | |||||
| Long-Term Debt | $1.29B | $0 | $0 | $1.83M | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $4.63M | $0 |
| Long-Term Deferred Tax Liabilities | $98.06M | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $197.97M | $138K | $5.88M | -$546 | $0 |
| Total Long-Term Liabilities | $1.58B | $245K | $5.88M | $6K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.28B | $10.99M | $7.68M | $10.09M | $193K |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $503K | $14K | $7K | $6K | $331 |
| Retained Earnings | $1.41B | -$29.1M | -$11.3M | -$10.77M | -$4K |
| Comprehensive Income & Other | -$97.2M | $414K | $411K | $675K | $0 |
| Other Stockholders' Equity | -$141.65M | $22.29M | $10.84M | $675K | $25K |
| Total Equity | $1.26B | -$6.79M | -$457K | -$10.09M | $21K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $3.54B | $4.19M | $7.22M | $5K | $213K |
| Supplementary Data | |||||
| Total Debt | $1.29B | $7.46M | $985K | $2.01M | $177K |
| Net Debt | $895.78M | $6.9M | -$3.24M | $2K | $129K |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$39.22M | -$17.8M | -$535K | -$4.89M | -$3.66M |
| Depreciation & Amortization | $2.42M | $457K | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $2.18M | $1.63M | $199K | $0 | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $434K | $1.23M | $215K | $0 | $0 |
| Other Working Capital | $4.29M | -$1.37M | -$2.73M | $596K | $1.36M |
| Total Working Capital Change | $4.73M | -$142K | -$2.52M | $596K | $1.36M |
| Other Non-Cash Items | $14.33M | $6.17M | -$4.87M | $2.02M | $149K |
| Net Cash from Operating | -$15.55M | -$9.68M | -$7.72M | -$2.27M | -$2.15M |
| Investing Activities | |||||
| Capital Expenditures | -$405K | -$51K | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | -$490K | $0 | $0 | $0 |
| Sales of Investments | $0 | $498K | $497K | $148K | $0 |
| Other Investing Activities | -$403K | $0 | $228K | -$331K | $0 |
| Net Cash from Investing | -$808K | -$43K | $725K | -$183K | $0 |
| Financing Activities | |||||
| Debt Repaid | - | - | - | -$1.11M | -$688K |
| Common Stock Issuance | $19.7M | $3.33M | $150K | $1.34M | $1.21M |
| Common Stock Repurchases | -$106K | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $289K | $8.49M | $0 | $0 |
| Net Cash from Financing | $17.42M | $6.07M | $10.93M | $2.45M | $1.9M |
| Forex Effect | -$104K | -$16K | $299K | $1K | $1K |
| Net Change in Cash | $955K | -$3.67M | $4.23M | $0 | -$252K |
| Supplementary Data | |||||
| Operating Cash Flow | -$15.55M | -$9.68M | -$7.72M | -$2.27M | -$2.15M |
| Capital Expenditure | -$2.4M | -$51K | $0 | $0 | $0 |
| Free Cash Flow | -$17.96M | -$9.73M | -$7.72M | -$2.27M | -$2.15M |
| Cash at Beginning | $554K | $4.23M | $0 | $0 | $252K |
| Cash at End | $1.51M | $554K | $4.23M | $0 | $0 |